For citations:
Ananyeva L.P., Starovoytova M.N., Gaydukova I.Z., Lukina G.V., Zonova E.V., Eliseeva L.V., Fatkhullina G.F., Abdulganieva D.I., Krechikova D.G., Kropotina T.V., Nesmeyanova O.B., Vinogradova I.B., Zhugrova E.S., Ivanova L.V., Nikulenkova N.E., Ziganshin O.R., Plaksina T.V., Zlobin M.V., Grabovetskaya Yu.Yu., Soroka N.F., Ershova O.B., Povarova T.V., Anoshenkova O.N., Lutckii A.A., Zinkina-Orikhan A.V., Linkova Yu.N., Fokina E.A., Porozova A.A., Pukhtinskaia P.S., Eremeeva A.V. The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS. Rheumatology Science and Practice. 2025;63(2):158-167. (In Russ.) https://doi.org/10.47360/1995-4484-2025-158-167
Email this article 